- Home
- GAU vs FDMT Comparison
GAU vs FDMT Comparison
Compare GAU & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | FDMT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.0M | 695.3M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GAU | FDMT |
|---|---|---|
| Price | $2.09 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.08 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 3.1M | 590.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $82.77 | N/A |
| Revenue Next Year | $29.09 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.66 | $5.97 |
| 52 Week High | $3.62 | $14.00 |
Technical Indicators
Market Signals| Indicator | GAU | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 61.51 |
| Support Level | $1.96 | $9.63 |
| Resistance Level | $2.75 | $11.89 |
| Average True Range (ATR) | 0.09 | 0.61 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 82.41 | 93.42 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).